Health Care Delivery

"The government really didn't rise to the challenge the way that it should have,” notes Ben Jones, vice president of government relations and public policy for The US Oncology Network. “Practices were in distress…stretching all resources to figure out workarounds."

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, is 1 of 6 cochairs for the 2024 Community Oncology Conference, and here she discusses how meeting content has incorporated ongoing coverage of the extremely disruptive cyberattack and how there is still so much work to be done.

A new study found that tumor sites in stage I-III colorectal cancer (CRC) could affect recurrence-free survival and survival after recurrence in patients.

A retrospective study analyzing tissue assays from patients with cutaneous melanoma demonstrated the promise of yes-associated protein (YAP) as a predictive biomarker for melanoma prognosis.

Jonathan E. Levitt, Esq, founding partner of boutique health care law firm Frier Levitt, LLC, discusses a recent class-action lawsuit brought against Johnson & Johnson in which an employee alleged a breach of fiduciary duty regarding her employer-sponsored pharmacy benefits.

Among adults with newly diagnosed cancer, rates of low-value cancer services persisted throughout the COVID-19 pandemic in areas ranging from peridiagnosis imaging to end-of-life care.

Judy Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance (COA), addresses the challenges pharmacies face in managing formularies to provide optimal patient care.

After moderating the panel discussion at The American Journal of Managed Care®’s Institute for Value-Based Medicine® (IVBM) event held in partnership with Banner|Aetna, Sandra Stein, MD, chief medical officer of Banner Health Plans, shared her key takeaway.

The newest treatment approved for amyotrophic lateral sclerosis (ALS) will be withdrawn from the market due to negative clinical trial results; former President Trump’s surgeon general is advocating for conservative states to support needle exchanges; new US hepatitis C infections dropped slightly in 2022 after more than a decade of steady increases.

Enhancing coordination of care has the potential to increase the value of heart failure care.

A cluster analysis demonstrated the potential for the Multiple Sleep Latency Test (MSLT) to aid in the diagnosis of central hypersomnia and distinguish between idiopathic hypersomnia subgroups.

Pat Van Burkleo, executive director of Feeding Louisiana, shares the key topics addressed during the Ochsner Health IVBM panel discussion on initiatives to increase food access in communities across the state.

A retrospective study reveals that measures of cognitive function, specifically processing speeds, decline in individuals with sickle cell disease as they grow older.

Average prices are substantially higher but rates of complications are similar in hospital-based vs freestanding surgery centers for colonoscopy, arthroscopy, and cataract removal surgery.

A new study found that adults in custody of the Federal Bureau of Prisons have seen improved pre-exposure prophylaxis (PrEP) initiation and sustained treatment uptake for HIV.

This new report helps clarify the ways in which the disease—and its treatment—affects the lives of children.

Engaging specialty physicians is an emerging area of focus for Medicare accountable care organizations. Enhanced data on specialist costs and outcomes are essential to addressing alignment challenges.

This analysis found the complex decision-making process of lung cancer screening among eligible individuals is infused with 3 principal themes that may influence how primary care physicians approach patients with comorbidities.

“Policies that require and reimburse universal mental health screening at postpartum visits, ensure connection to care, reduce gaps in postpartum insurance coverage, and require clinician training in culturally responsive resources could improve equity of postpartum depression diagnoses and care in the US,” study authors wrote.

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).

"If someone is food insecure for a long period of time, then they may be consuming foods that aren't as nutritious and support their health and growth as they should," Denise Holston, PhD, explains in an interview.

With the 2024 Community Oncology Conference, from the Community Oncology Alliance (COA), set to kick off this week in Orlando, Florida, The American Journal of Managed Care® spoke with Emily Touloukian, DO, COA board member and 1 of 6 cochairs for this year’s meeting, on highlights from the packed agenda and the power of advocacy.

Part 1 of a 3-part feature series on the history, evolution, and current state of LGBTQ+ health care is focused on the unique needs and journey of transgender patients in the US health system, as well as the policies and social influences that have shaped their access to care.

A cross-sectional study utilizing self-reports from Chinese college students correlated mobile phone use with insomnia, bolstering previous research that made similar conclusions.

An artificial intelligence (AI) mode was more accurate in assessing patient risks for skin cancer through the analysis of 2D facial images compared with more traditional risk-factor screening.

The Center on Health Equity and Access shares up-to-date news, research progress, and ongoing initiatives dedicated to tackling health care disparities and enhancing overall access to quality care.

The often-overlooked perspective of the caregiver was brought to the forefront of a presentation by Julia Cohen Sebastien at the Greater Philadelphia Business Coalition on Health 2024 Women’s Health Summit.

Results are consistent with the authors' prior findings on the possible effects of circadian rhythm on outcomes after immunotherapy.

A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.

Patrick Vermersch, MD, PhD, University of Lille, France details the adverse events observed in the frexalimab trials and the next steps necessary to establish frexalimab as a standard of care in multiple sclerosis (MS) in the third and final part of an interview.